AnGes Stock

AnGes EBIT Margin

The EBIT Margin (Operating Margin) of AnGes (4563.T) as of Sep 5, 2026 is -1,415.31 %. In the previous year, EBIT Margin (Operating Margin) was -7,822.66 % — a change of -81.91% (higher).

EBIT Margin

-1,415.31 %

YoY

-81.91%

Last updated:

EBIT Margin (Operating Margin) of AnGes is 2026 -1,415.31 % . EBIT Margin (Operating Margin) of AnGes was 2025 -7,822.66 % . It decreases by -81.91% higher compared to the previous year.

For AnGes, the operating (EBIT) margin of -1,415.3% is up versus -13,999.2% a few years ago.

The AnGes EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
-900.56 JPY
Jan 1, 2018
-502.46 JPY
Jan 1, 2019
-1,000.74 JPY
Jan 1, 2020
-13,999.18 JPY
Jan 1, 2021
-24,358.89 JPY
Jan 1, 2022
-24,320.76 JPY
Jan 1, 2023
-7,822.66 JPY
Jan 1, 2024
-1,415.31 JPY
The AnGes EBIT Margin history
YEAREBIT MarginYoY
-1,415.31 %-81.91%
-7,822.66 %-67.84%
-24,320.76 %-0.16%
-24,358.89 %+74.00%
-13,999.18 %+1,298.88%
-1,000.74 %+99.17%
-502.46 %-44.21%
-900.56 %-2.77%
-926.24 %-4.50%
-969.88 %+288.10%
-249.91 %+8,906.68%
-2.77 %-30.92%
-4.02 %-53.46%
-8.63 %+23.17%
-7.01 %+57.19%
-4.46 %+53.82%
-2.90 %+144.40%
-1.19 %+126.71%
-0.52 %-35.50%
-0.81 %
Access this data via the Eulerpool API

AnGes Stock analysis

What does AnGes do? AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AnGes stock

EBIT Margin (Operating Margin) of AnGes is -1,415.31 % in 2026.

EBIT Margin (Operating Margin) of AnGes changed from -7,822.66 % to -1,415.31 %, representing a -81.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) AnGes since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s AnGes with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — AnGes

All Key Metrics — AnGes